Nordic Pharma Celebrates Treatment of 100,000 Patients by Enhancing Its Lacrifill® Offering

Nordic Pharma's Ambitious Milestone: 100,000 Patients Treated

In a significant development in eye care, Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., recently announced a remarkable milestone: over 100,000 patients have been treated with their innovative Lacrifill® Canalicular Gel. This achievement underscores the product's acceptance among healthcare professionals and highlights the company's commitment to improving patient outcomes in the management of dry eye symptoms.

Over the past two years, Lacrifill® has become a critical tool in the treatment of dry eye disease, which affects approximately 6.8% of adults in the United States. In response to feedback from physicians, Nordic Pharma has enhanced its product offering by including cannulas with the shipment of Lacrifill® syringes. This addition aims to improve the convenience and efficiency of the treatment process for eye care providers.

Lacrifill® Canalicular Gel, a proprietary cross-linked hyaluronic acid derivative, is delivered in pre-filled syringes that allow for precise application in treating dry eye symptoms. Previously, physicians had expressed the need for a more user-friendly application method, resulting in the integration of cannulas that facilitate the insertion of the gel into the patients' ocular surfaces. This advancement has been well-received, further establishing the gel's role as a potent option in contemporary ocular surface disease management.

Dr. Eric Donnenfeld, Board Chair at OCLI Vision and NYU Langone Health, emphasizes the importance of actively managing patients’ ocular surface health, particularly during surgical interventions. He asserts that Lacrifill® is not another run-of-the-mill punctal plug, but a groundbreaking solution that can significantly impact visual outcomes and patient comfort. This view is echoed by Dr. Mile Brujic of Premier Vision Group, who highlights the gel's versatility as both an everyday treatment and a complementary tool in surgical patient management.

The product’s efficacy lies in its ability to temporarily block tear drainage by occluding the canalicular system, thereby retaining moisture on the eye surface. The gel is designed to flow from the punctum into the lacrimal sac, creating a protective barrier that alleviates the discomfort associated with dry eye disease.

Nordic Pharma first launched Lacrifill® in May 2024 after receiving FDA clearance, and the rapid adoption by optometrists and ophthalmologists has exceeded expectations. Each package of Lacrifill® now comes with ten cannulas, ensuring that healthcare providers have the necessary tools for effective and comfortable treatment.

To showcase its product further, Nordic Pharma will be hosting live demonstrations at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting. These demonstrations will allow eye care professionals to view firsthand how Lacrifill® Gel can be effectively integrated into their practice. Live sessions are scheduled from April 10 to April 12 in Washington, DC, engaging industry leaders such as Dr. Neel Desai and Dr. Mina Farahani, who will provide insights and practical applications.

This forward-thinking approach positions Nordic Pharma as a leader in the eye care industry, focusing not only on innovative products but also on enhancing the overall treatment experience for both professionals and patients alike. With plans for further advancements and increased accessibility to specialty eye care solutions, Nordic Pharma continues to explore avenues for growth and improvement in ocular health management.

For more information on Lacrifill® Canalicular Gel, visit lacrifill.com.